XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2021:
Contract Asset
Contract asset, January 1, 2021$7,430 
Transferred to trade receivable of contract asset included in beginning of the year contract asset(7,430)
Contract asset, net of transferred to trade receivables on contracts during the period8,378 
Contract asset, September 30, 2021
$8,378 
Contract Liability
Contract liability, January 1, 2021$11,961 
Recognition of revenue included in beginning of year contract liability$(4,291)
Contract liability, net of revenue recognized on contracts during the period3,694 
Foreign currency translation(26)
Contract liability, September 30, 2021
$11,338 
Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2021 and 2020 (dollar amounts in thousands):
Three Months Ended September 30, 2021Three Months Ended September 30, 2020Nine Months Ended September 30, 2021Nine Months Ended September 30, 2020
Neurosurgery$199,210 $189,674 $591,064 $516,048 
Instruments57,287 49,649 163,511 124,493 
Total Codman Specialty Surgical256,497 239,323 754,575 640,541 
Wound Reconstruction and Care(2)
99,744 82,115 291,058 210,673 
Extremity Orthopedics(1)
— 21,922 — 54,556 
Private Label30,620 26,872 91,291 77,451 
Total Tissue Technologies130,364 130,909 382,349 342,680 
Total revenue$386,861 $370,232 $1,136,924 $983,221 
(1) On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. In conjunction with the sale of this business, the Company rebranded the Orthopedics and Tissue Technologies segment as Tissue Technologies in the first quarter of 2021. See Note 2. Acquisitions and Divestitures, for details.
(2) See Note 2. Acquisitions and Divestitures, for details around the ACell acquisition.